# Axogen Inc. (AXGN)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.95B  
**Price:** $42.38 (+2.52%)

> Axogen Inc. is a leading developer and marketer of innovative surgical solutions for peripheral nerve regeneration and repair. The company specializes in biologically active technologies, including the Avance Nerve Graft, an off-the-shelf processed human nerve allograft that bridges severed peripheral nerves without requiring a second surgical site. Its portfolio also features the AxoGuard Nerve Connector and AxoGuard Nerve Protector, porcine submucosa extracellular matrix products that enable tensionless nerve repairs and protection; the AxoGuard Nerve Cap for nerve end treatment; and the Avive Soft Tissue Membrane for soft tissue management. Additionally, Axogen offers the AxoTouch Two-Point Discriminator, a tool for assessing skin innervation density. These products serve hand surgeons, reconstructive plastic surgeons, oral and maxillofacial surgeons, and other specialists treating nerve injuries across the body. Axogen Inc. provides these solutions to healthcare providers in the United States, Canada, Europe, South Korea, and other international markets, aiming to restore nerve function, sensation, and patient quality of life. Headquartered in Alachua, Florida, the company focuses on advancing peripheral nerve repair as a standard of care in surgical practice.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $225M | $167M | -$8M | -$16M | — |
| 2024 | $187M | $142M | -$3M | -$10M | — |
| 2023 | $159M | $122M | -$21M | -$22M | — |
| 2022 | $139M | $109M | -$30M | -$29M | — |
| 2021 | $127M | $104M | -$25M | -$27M | — |
| 2020 | $112M | $91M | -$23M | -$24M | — |
| 2019 | $107M | $89M | -$31M | -$29M | — |
| 2018 | $84M | $71M | -$21M | -$22M | — |
| 2017 | $60M | $51M | -$8M | -$10M | — |
| 2016 | $41M | $35M | -$8M | -$14M | — |
| 2015 | $27M | $22M | -$9M | -$13M | — |
| 2014 | $17M | $13M | -$10M | -$18M | — |
| 2013 | $11M | $9M | -$10M | -$15M | — |
| 2012 | $8M | $6M | -$8M | -$9M | — |
| 2011 | $5M | $2M | -$7M | -$9M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $222M | $93M | $129M | $36M | $48M |
| 2024 | $204M | $100M | $104M | $28M | $47M |
| 2023 | $197M | $101M | $96M | $31M | $47M |
| 2022 | $195M | $94M | $101M | $15M | $46M |
| 2021 | $208M | $95M | $113M | $33M | $45M |
| 2020 | $201M | $78M | $123M | $49M | $32M |
| 2019 | $155M | $22M | $132M | $36M | — |
| 2018 | $160M | $13M | $147M | $24M | $35,000 |
| 2017 | $59M | $34M | $25M | $37M | $20M |
| 2016 | $46M | $31M | $15M | $30M | $20M |
| 2015 | $37M | $29M | $8M | $26M | $25M |
| 2014 | $16M | $28M | -$11M | $8M | $25M |
| 2013 | $28M | $28M | $136,633 | $20M | $25M |
| 2012 | $20M | $23M | -$3M | $14M | $22M |
| 2011 | $12M | $6M | $6M | $8M | $5M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $812,000 | $4M | -$3M |
| 2024 | $5M | $3M | $1M |
| 2023 | -$6M | $14M | -$20M |
| 2022 | -$16M | $20M | -$36M |
| 2021 | -$13M | $28M | -$41M |
| 2020 | -$10M | $22M | -$32M |
| 2019 | -$20M | $5M | -$25M |
| 2018 | -$18M | $6M | -$24M |
| 2017 | -$9M | $1M | -$10M |
| 2016 | -$11M | $931,000 | -$12M |
| 2015 | -$13M | $408,782 | -$13M |
| 2012 | -$9M | $48,459 | -$9M |
| 2011 | -$7M | $20,610 | -$7M |
| 2010 | -$4M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/AXGN)